Estadístiques de Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Visites totals
| views | |
|---|---|
| Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy | 42 |
Visites totals per mes
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 1 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Barratt_kid_resu.pdf | 21 |
| Barratt_kid_resu.pdf(legacy) | 19 |
Vistes principals per país
| views | |
|---|---|
| United States | 22 |
| Spain | 12 |
| Australia | 4 |
| Netherlands | 3 |
| China | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Barcelona | 12 |
| Mountain View | 7 |
| San Ramon | 5 |
| Menlo Park | 2 |
| Ann Arbor | 1 |
| Ashburn | 1 |
| Cambridge | 1 |
| Dearborn | 1 |
| Dickson | 1 |
| Fairfield | 1 |
| Portland | 1 |
| San Diego | 1 |
| Shenzhen | 1 |